Literature DB >> 29320975

Systemic lupus erythematosus with inflammatory bowel disease-ulcerative colitis: case report.

H Elsayed Mansour1, S Gamal Arafa1, W Abdelfatah Shehata1.   

Abstract

A 30-year-old female presented to the rheumatology outpatient clinic of the Internal Medicine Department, Ain Shams University Hospital, Cairo, Egypt, complaining of a large right leg ulcer consistent with pyoderma gangrenosum. There was history of recurrent attacks of bleeding per rectum of one-year duration. During hospitalization she noticed blurring of vision in the left eye with diffuse blackish discoloration of the feet and toes, consistent with small-vessel vasculitis. Colonoscopy with biopsy and histopathology confirmed the diagnosis of inflammatory bowel disease-ulcerative colitis (IBD-UC). Meanwhile, the patient fulfilled the SLICC classification criteria for systemic lupus erythematosus (SLE): recurrent oral ulcers, positive antinuclear antibody testing, proteinuria >0.5 gm/24-hour urine, positive test for lupus anticoagulant and consumed C3 complement component. Herein we report a rare case of coexistence of SLE and IBD-UC.

Entities:  

Keywords:  SLE; Ulcerative colitis; coexistence

Mesh:

Substances:

Year:  2018        PMID: 29320975     DOI: 10.1177/0961203317751857

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

1.  Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value.

Authors:  Saiyan Jin; Changcheng Yu; Beiwei Yu
Journal:  Am J Transl Res       Date:  2021-04-15       Impact factor: 3.940

2.  Coexistence of Lupus Nephritis, Ulcerative Colitis, and Communicating Hydrocephalus: A Report of a 21-Year-Old Male.

Authors:  Bushra Ali Khan; Nida Saleem; Danyal Hassan; Shabaz Kiani; Muhammad Haneef
Journal:  Case Rep Nephrol       Date:  2022-02-04

Review 3.  Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine.

Authors:  Melisa Intan Barliana; Nadiya Nurul Afifah; Riezki Amalia; Laniyati Hamijoyo; Rizky Abdulah
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.